Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 2/20 | 0.52 |
| ▸ | SYK | P43405 | 2/20 | 0.50 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.46 |
| ▸ | ATP4A | P20648 | 1/20 | 0.44 |
| ▸ | ATP4B | P51164 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3303654 | 0.84 | CYP19A1 (0.51) | SYKTLR8TLR7ATP4AATP4B | |
| SCHEMBL1484069 | 0.79 | CYP1A1 (0.57) | CYP1A1SYKATP4AATP4BKDM4E | |
| SCHEMBL3347682 | 0.75 | KMT2A (0.49) | TLR8TLR7 | |
| SCHEMBL27961477 | 0.75 | KMT2A (0.51) | PDPK1FLT3 | |
| SCHEMBL30869753 | 0.75 | CYP1A1 (0.68) | CYP1A1KDM4EPDPK1ALDH1A1LMNA | |
| SCHEMBL1421592 | 0.73 | TDO2 (0.53) | CYP1A1SYKTLR8TLR7KIT | |
| SCHEMBL30074643 | 0.71 | KMT2A (0.58) | KDM4EALDH1A1HPGDTSHRKIT | |
| SCHEMBL319254 | 0.71 | KMT2A (0.58) | KDM4EALDH1A1HPGDTSHRKIT | |
| SCHEMBL4768283 | 0.71 | KMT2A (0.57) | TLR8TLR7TSHR | |
| SCHEMBL1606556 | 0.71 | CYP19A1 (0.68) | CYP1A1MAPTVCPIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121655-A1 | NOVEL 2-HETEROARYL SUBSTITUTED INDOLES 695 | AstraZeneca AB (SE) | 2009-11-25 | — | — | EP | claimed |
| WO-2008108729-A1 | NOVEL 2-HETEROARYL SUBSTITUTED INDOLES 695 | ASTRAZENECA AB (SE) | 2008-09-12 | — | — | WO | claimed |
| US-20100098631-A1 | Novel-2-Heteroaryl Substituted Indoles 695 | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | US | disclosed |
| US-20100098631-A1 | Novel-2-Heteroaryl Substituted Indoles 695 | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | US | disclosed |
| US-20100098631-A1 | Novel-2-Heteroaryl Substituted Indoles 695 | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | US | disclosed |
| CN-101636395-A | Novel 2-heteroaryl substituted indoles 695 | ASTRAZENECA AB | 2010-01-27 | — | — | CN | disclosed |
| EP-2121655-A1 | NOVEL 2-HETEROARYL SUBSTITUTED INDOLES 695 | AstraZeneca AB (SE) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008108729-A1 | NOVEL 2-HETEROARYL SUBSTITUTED INDOLES 695 | ASTRAZENECA AB (SE) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008108729-A1 | NOVEL 2-HETEROARYL SUBSTITUTED INDOLES 695 | ASTRAZENECA AB (SE) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100098631-A1 | Novel-2-Heteroaryl Substituted Indoles 695 | APP, IDO2, IDO1 | CYP1A1 920/4885SYK 2268/4885TLR8 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.